Skip to content

Study · Non-randomized trial · n = 12 · 2001

2 results

Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report.

Pereyra Pacheco B, Méndez Ribas JM, Milone G, Fernández I, Kvicala R, Mila T, Di Noto A, Contreras Ortiz O, Pavlovsky S

Gynecologic oncology1 Jun 2001Cited by 95 (Europe PMC)

PMID11371127 (opens in a new tab)DOI10.1006/gyno.2001.6181 (opens in a new tab)PepBankPUB-11371127
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenarchal cancer patients, normal ovulatory cycles continued after withdrawal of leuprolide treatment given before and during chemotherapy.

    In plain wordsIn postmenarchal cancer patients, normal ovulatory cycles continued after leuprolide withdrawal following chemotherapy.

    Peptide
    Leuprolide
    Outcome
    Not applicableNormal ovulatory cycles after withdrawal
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Monthly depot injection with simultaneous 0.2 mg injectionAs given in this study (human).

    Source sentences

    Summary
    After GnRH analog withdrawal, Group B patients continued with normal ovulatory cycles.
    2 context sentences
    Summary · context
    Postmenarchal patients (Group B), aged 14.7 to 20 years (n = 12) with normal menstrual rhythm and ovulatory cycles, received treatment with GnRH analogs prior to PCT.
    Summary · context
    All groups received the PCT regimens CAVPE, CVPP, ABVD, TAMO, ARA-C, and MTT. In group B, leuprolide acetate inhibition was obtained with a depot injection administered each month before and during treatment with PCT. To accelerate the timing of ovarian regression, a subcutaneous injection (0.2 mg)…
  2. 02HumanNon-randomized trialEfficacy outcome

    In the postmenarchal cancer group receiving leuprolide before and during chemotherapy, two patients became pregnant.

    In plain wordsIn postmenarchal cancer patients receiving leuprolide with chemotherapy, two patients later became pregnant.

    Peptide
    Leuprolide
    Outcome
    Not applicablePregnancy after treatment
    Study

    n = 12

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Monthly depot injection with simultaneous 0.2 mg injectionAs given in this study (human).

    Measurements

    Pregnancies
    2 patients
    Group B

    Source sentences

    Summary
    Two patients became pregnant.
    2 context sentences
    Summary · context
    Postmenarchal patients (Group B), aged 14.7 to 20 years (n = 12) with normal menstrual rhythm and ovulatory cycles, received treatment with GnRH analogs prior to PCT.
    Summary · context
    All groups received the PCT regimens CAVPE, CVPP, ABVD, TAMO, ARA-C, and MTT. In group B, leuprolide acetate inhibition was obtained with a depot injection administered each month before and during treatment with PCT. To accelerate the timing of ovarian regression, a subcutaneous injection (0.2 mg)…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.